Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 7/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132562 | 0.88 | CETP (0.40) | CETP | |
| SCHEMBL129892 | 0.87 | CETP (0.36) | CETPHTR2CSLC6A4HTR2BSLC1A5 | |
| SCHEMBL1588216 | 0.87 | HTR2C (0.39) | CETPHTR2CSLC6A4HTR2BLRRK2 | |
| SCHEMBL129204 | 0.85 | CETP (0.39) | CETP | |
| SCHEMBL130203 | 0.84 | CETP (0.45) | CETPHTR2CSLC6A4HTR2BLRRK2 | |
| SCHEMBL1588309 | 0.83 | CETP (0.44) | CETPLRRK2PTGER1 | |
| SCHEMBL1587844 | 0.83 | SLC6A4 (0.43) | CETPHTR2CSLC6A4HTR2BLRRK2 | |
| SCHEMBL12062624 | 0.82 | CETP (0.57) | CETP | |
| SCHEMBL4510002 | 0.81 | NR3C1 (0.37) | CETP | |
| SCHEMBL131232 | 0.80 | CETP (0.58) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979331-B1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | NAKAMURA YOSHINORI | 2011-04-21 | — | — | US | disclosed |
| US-7906517-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1979331-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | CETP, MTTP, APOB | CETP 1/4885HTR2C 3167/4885SLC6A4 1347/4885 |
| US-20090029994-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | CETP 1/4885HTR2C 3167/4885SLC6A4 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.